Calquence tablet formulation approved in the US across current indications, clinical data shows tablet bioequivalent to capsule

MSK and City of Hope researchers develop test using machine learning to help predict immunotherapy response in lymphoma

Researchers with Memorial Sloan Kettering and City of Hope have created a tool that uses machine learning to assess a non-Hodgkin lymphoma patient’s likely response to chimeric antigen receptor T-cell therapy before starting the treatment, according to study results published on April 1 in Nature Medicine.

April 11, 2025

Vol.51 No.14

Clinical Roundup

NK cells complexed with bispecific antibody yield high response rates in lymphoma

A novel cell therapy approach using cord blood-derived natural killer cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from the University of Texas MD Anderson Cancer Center.

April 11, 2025

Vol.51 No.14

Drugs & Targets

CHMP recommends approval of Calquence plus chemoimmunotherapy for first-line mantle cell lymphoma

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the EU for the treatment of adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous hematopoietic stem cell transplantation.

April 04, 2025

Vol.51 No.13

Clinical Roundup

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Orca Bio, a late-stage biotechnology company, on March 17 announced results from the pivotal phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome and mixed-phenotype acute leukemia. Orca-T is manufactured using highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.

March 28, 2025

Vol.51 No.12

Drugs & Targets

EC expands approval for Breyanzi for r/r follicular lymphoma

The European Commission has granted approval to Breyanzi, a CD19-directed CAR T-cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

March 21, 2025

Vol.51 No.11

Accelerating translational research in leukemia: The City of Hope approach

As a physician-scientist, I navigate the intersection of laboratory research and clinical care every day. At City of Hope, our mission is to rapidly translate groundbreaking discoveries into effective treatments for patients with hematologic malignancies, particularly acute leukemias. This is possible due to a unique combination of infrastructure and culture combined with an unwavering sense of urgency.

March 14, 2025

Vol.51 No.10

By Guido Marcucci